PPP2R2C Antibody

What is PPP2R2C and why is it significant in cellular research?

PPP2R2C (protein phosphatase 2, regulatory subunit B, gamma isoform) is a substrate-binding regulatory subunit of the protein phosphatase 2A (PP2A) holoenzyme complex. It has emerged as a significant tumor suppressor, particularly in prostate cancer research. Studies have demonstrated that loss of PPP2R2C promotes androgen ligand depletion-resistant prostate cancer growth without altering androgen receptor (AR) expression or canonical AR-regulated gene expression . This unique property positions PPP2R2C as a critical player in understanding androgen-pathway independent growth mechanisms in cancer cells, making it an important target for researchers investigating treatment-resistant cancers .

What applications can the PPP2R2C antibody be used for in research settings?

The PPP2R2C antibody has been validated for multiple research applications, including:

For optimal results, it is recommended to titrate the antibody concentration for each specific experimental setting and sample type, as reactivity can vary depending on the tissue origin and preparation method .

What sample types have been successfully tested with PPP2R2C antibodies?

PPP2R2C antibodies have demonstrated reliable reactivity across multiple species and sample types:

Western blot analysis has confirmed detection of PPP2R2C at its expected molecular weight of approximately 49 kDa across these sample types .

How should antigen retrieval be optimized for PPP2R2C immunohistochemistry?

Effective antigen retrieval is crucial for reliable PPP2R2C detection in formalin-fixed paraffin-embedded (FFPE) tissues. Based on published protocols, the recommended approach involves:

Primary method: Use TE buffer at pH 9.0 for heat-induced epitope retrieval. This has been validated for human breast cancer tissue, brain tissue, and testis tissue samples .

Alternative method: If TE buffer proves suboptimal, citrate buffer at pH 6.0 can be employed as an alternative retrieval solution . In published research, this method was successfully used for PPP2R2C detection on tissue microarrays (TMAs) in a pressure cooker setting .

The complete IHC protocol should include:

• Deparaffinization and rehydration of FFPE sections

• Quenching of endogenous peroxidases (using 3% hydrogen peroxide)

• Avidin/biotin blocking

• Antigen retrieval as described above

• Blocking with appropriate normal serum

• Primary antibody incubation (30 minutes at room temperature)

• Detection with biotinylated secondary antibodies and ABC reagent

• Visualization with DAB chromogen

• Counterstaining with hematoxylin

When assessing nuclear staining of PPP2R2C, a 0-3 intensity scale has been established in previous research, with 3 representing intense nuclear staining .

What controls should be included when working with PPP2R2C antibodies?

To ensure experimental rigor when using PPP2R2C antibodies, the following controls should be incorporated:

For Western blotting applications, loading controls should include housekeeping proteins appropriate to the subcellular fraction being analyzed, considering PPP2R2C's predominant nuclear localization .

How should researchers optimize PPP2R2C antibody dilutions for different applications?

Antibody dilution optimization is critical for obtaining specific signals while minimizing background. For PPP2R2C antibodies:

Western Blot: Begin with the manufacturer's recommended range (1:500-1:2000) and perform a dilution series to determine optimal signal-to-noise ratio . Consider sample type when optimizing - cell lines may require different concentrations than tissue lysates.

Immunohistochemistry: Start with a broader range (1:20-1:200) and titrate based on your specific tissue type and fixation method . For nuclear proteins like PPP2R2C, optimization of antigen retrieval and antibody concentration must be performed in conjunction.

A systematic approach includes:

• Preparing a dilution series spanning the recommended range

• Testing on known positive and negative samples

• Evaluating signal intensity, specificity, and background

• Selecting the dilution that maximizes specific signal while minimizing non-specific background

As noted in the product information, "it is recommended that this reagent should be titrated in each testing system to obtain optimal results" as performance can be sample-dependent .

How can researchers distinguish between specific and non-specific staining patterns for PPP2R2C?

Distinguishing genuine PPP2R2C signal from artifacts requires careful assessment of staining patterns and appropriate controls:

Specific PPP2R2C staining characteristics:

• Predominantly nuclear localization based on immunohistochemical analyses of prostate tissues

• Homogeneous staining within individual tumor cores as observed in TMA studies

• Observable in established positive control samples (HeLa cells, MCF-7 cells, testis tissue)

• Detectable at the expected molecular weight (49 kDa) by Western blot

To confirm specificity:

• Compare staining patterns with published results showing nuclear PPP2R2C expression in LNCaP and VCaP cell lines

• Assess correlation between staining intensity and signal in orthogonal assays (e.g., WB and IHC should show concordant results)

• Verify absence of signal in negative controls

• Confirm protein size matches the calculated molecular weight (49 kDa from 430 amino acids)

Non-specific binding may manifest as diffuse cytoplasmic staining, inconsistent staining patterns between similar samples, or multiple unexpected bands on Western blots.

What are common technical challenges in PPP2R2C protein detection and how can they be addressed?

Researchers frequently encounter several technical challenges when working with PPP2R2C:

When troubleshooting, it's important to remember that nuclear proteins like PPP2R2C may require specialized protocols for consistent detection. Published studies have employed pressure cooker-based antigen retrieval methods to achieve reliable nuclear staining .

How should researchers quantify and statistically analyze PPP2R2C expression data?

Accurate quantification of PPP2R2C expression is essential for correlation with biological outcomes:

For IHC quantification:

• Use established scoring systems such as the 0-3 nuclear intensity scale employed in previous research

• Ensure scoring by trained pathologists (e.g., genitourinary pathologists for prostate samples)

• Consider both staining intensity and percentage of positive cells

• Distinguish between nuclear and any cytoplasmic staining

For statistical analysis:

• Clearly define cutoff values for categorizing expression levels (e.g., low vs. high expression)

• Apply appropriate statistical models for correlations with clinical variables (e.g., Proc Mixed model adjusted for relevant covariates like PSA levels and tumor stage)

• For survival analysis, use Kaplan-Meier curves with logrank tests to assess significance of expression patterns

• Report adjusted p-values and confidence intervals for all comparisons

In published research on prostate cancer, patients were stratified into groups with high PPP2R2C (mean staining intensity ≥ 1) and low PPP2R2C (mean staining intensity < 1) for survival analysis, which revealed significant differences in outcomes (logrank test P=0.045) .

How can PPP2R2C antibodies be used to investigate protein-protein interactions in the PP2A complex?

Investigating PPP2R2C's role within protein phosphatase complexes can be accomplished through several advanced approaches:

Co-immunoprecipitation (Co-IP): PPP2R2C antibodies have been validated for Co-IP applications , allowing isolation of native protein complexes containing PPP2R2C. This approach can identify:

• Interactions with other PP2A subunits (structural and catalytic)

• Novel binding partners that may regulate PPP2R2C function

• Changes in complex formation under different cellular conditions

To optimize Co-IP experiments:

• Use mild lysis conditions to preserve protein-protein interactions

• Pre-clear lysates to reduce non-specific binding

• Compare results using different antibody epitopes to confirm specificity

• Include appropriate negative controls (non-specific IgG, lysates from cells with PPP2R2C knockdown)

• Validate key interactions using reciprocal Co-IP with antibodies against interacting partners

Proximity ligation assays (PLA) can provide additional spatial information about PPP2R2C interactions within the cell, particularly important for understanding nuclear versus cytoplasmic functions of this predominantly nuclear protein .

What methodologies can be employed to study PPP2R2C's role in cancer resistance mechanisms?

Given PPP2R2C's established role in promoting androgen-independent growth in prostate cancer , several methodologies can elucidate its function in treatment resistance:

A particularly valuable approach demonstrated in published research combined PPP2R2C knockdown with AR antagonist (MDV3100) treatment, which revealed that growth induced by PPP2R2C loss was not inhibited by AR antagonism. This suggests PPP2R2C modulates pathways independent of canonical AR signaling .

How can PPP2R2C antibodies be integrated into multi-parameter analyses of tumor samples?

Incorporating PPP2R2C detection into comprehensive tumor analyses offers deeper insights into its role in cancer biology:

Multiplex immunohistochemistry/immunofluorescence:

• Co-stain for PPP2R2C with other PP2A subunits to assess complex integrity

• Combine with markers of cell proliferation, apoptosis, or lineage to define cellular contexts

• Include AR pathway components to evaluate relationship to androgen signaling

Tissue microarray analysis:

• As demonstrated in prostate cancer research, TMAs enable high-throughput analysis of PPP2R2C expression across large patient cohorts

• Correlate PPP2R2C staining with clinicopathological features and outcomes

• Develop scoring systems (e.g., 0-3 nuclear intensity scale) for standardized assessment

Single-cell approaches:

• Integrate PPP2R2C antibodies into CyTOF or imaging mass cytometry panels

• Examine heterogeneity of expression within tumors

• Identify rare subpopulations with distinct PPP2R2C expression patterns

These multi-parameter approaches should be supported by appropriate statistical methods for multivariate analysis, as demonstrated in studies correlating PPP2R2C expression with prostate cancer outcomes (using adjusted models for PSA levels and tumor stage) .

What is the evidence for PPP2R2C as a potential biomarker in prostate cancer progression?

Research has established compelling evidence for PPP2R2C's potential as a prognostic biomarker in prostate cancer:

Clinical correlation studies: Analysis of radical prostatectomy tissues from 100 patients with long-term clinical follow-up demonstrated:

• Lower PPP2R2C staining significantly correlated with biochemical relapse (P≤0.01)

• Reduced PPP2R2C expression associated with development of distant metastases (P<0.001)

• Low PPP2R2C protein levels correlated with prostate cancer-specific mortality (P=0.048)

Survival analysis: Kaplan-Meier survival curves comparing patients with high PPP2R2C expression (mean staining intensity ≥ 1) versus low expression (mean staining intensity < 1) revealed:

• Significant survival advantage in patients with high PPP2R2C expression (logrank test P=0.045)

• This association persisted after adjusting for established prognostic factors

Expression pattern analysis: Microarray measurements of laser-capture microdissected tissues showed:

• PPP2R2C expression was 3.85-fold lower in primary tumors compared to benign prostate epithelia (P=0.034)

• Even greater reduction (5.69-fold) in metastatic castration-resistant prostate cancer compared to benign tissue (P<0.001)

These findings collectively suggest PPP2R2C could serve as an independent prognostic marker that identifies patients at higher risk for disease progression and cancer-specific mortality.

How does PPP2R2C antibody staining compare to other molecular markers in cancer diagnosis and prognosis?

Comparative analysis positions PPP2R2C as a distinct biomarker with unique properties:

Unlike traditional prostate cancer markers that directly reflect AR pathway activity, PPP2R2C appears to represent an orthogonal mechanism related to PP2A tumor suppressor function . This independence from canonical AR signaling makes PPP2R2C particularly valuable for identifying tumors likely to develop resistance to AR-targeting therapies.

Notably, while established markers like AR and PSA have well-defined roles in initial diagnosis, PPP2R2C's strongest associations appear to be with long-term outcomes and treatment resistance, suggesting complementary rather than redundant clinical utility .

What methodological considerations are critical when using PPP2R2C antibodies for tumor classification studies?

When employing PPP2R2C antibodies for tumor classification or biomarker studies, several methodological aspects warrant careful attention:

Standardization of immunohistochemical protocols:

• Consistent antigen retrieval (recommended: TE buffer pH 9.0 or citrate buffer pH 6.0)

• Standardized incubation times and temperatures (suggested: 30 minutes at room temperature)

• Defined detection systems (e.g., DAB as chromogen)

• Appropriate counterstaining for nuclear assessment (e.g., Meyer's hematoxylin)

Scoring methodology:

• Employ validated scoring systems (e.g., 0-3 nuclear intensity scale)

• Ensure assessment by trained pathologists

• Consider both staining intensity and distribution

• Establish clear cutpoints for classification (e.g., mean staining intensity ≥ 1 vs. < 1)

Statistical analysis:

• Adjust for established prognostic variables (e.g., PSA levels, tumor stage)

• Use appropriate statistical models (e.g., Proc Mixed model in SAS)

• Apply rigorous survival analysis methodology (Kaplan-Meier with logrank tests)

• Report hazard ratios with confidence intervals

Sample considerations:

• Include diverse tumor stages and grades

• Incorporate matched normal tissue controls

• Consider tissue microarrays for high-throughput screening

• Account for tumor heterogeneity through multiple sampling

These methodological considerations have proven effective in establishing PPP2R2C's prognostic value in prostate cancer studies and provide a framework for investigating its utility in other cancer types.